NGLY1-deficiency is a relatively newly discovered genetic disorder, with the first patient identified in 2012. The symptoms are severe, and include delayed development, disordered movement, low muscle tone and strength, and the inability to produce tears. Understanding how lack of NGLY1 leads to these symptoms is critical when considering targets for therapeutic interventions, and creating useful animal models of the disease is therefore equally important.
Researchers have developed a potential mouse model for the genetic disorder known as an NGLY1 deficiency. Published in the journal PLOS Genetics, the study describes how a complete knockout of the Ngly1 gene in mice leads to death just before birth, which can be partially rescued by a second knockout of another gene called Engase. When related genes in the mice used for making the knockouts are variable, the doubled-deletion mice survive and have symptoms that are analogous to humans with NGLY1-deficiency, indicating that these mice could be useful for testing potential therapies.
The team has already had some success studying the consequences of Ngly1 deficiency in cultured animal cells. The Ngly1 gene codes for an enzyme that helps remove sugar chains from proteins that are scheduled for degradation. Their research showed that when Ngly1 was absent, sugars normally removed by Ngly1 were improperly removed by another enzyme called ENGase. Knocking out the ENGase gene led to normal protein degradation.
In the current study, the researchers first examined the effects of knocking out Ngly1 in mice. They found that when mice lacked both Ngly1 genes--one from each parent--they always died just before birth. However, a double knockout of both Ngly1 and ENGase genes resulted in mice that survived after birth, but not for very long.
This positive result was actually unexpected. "We thought that ENGase acted further downstream to Ngly1 in the catabolism of glycoproteins" notes team leader, "and were surprised when the double knockout was able to suppress the lethality of Ngly1-KO mice. If ENGase was merely an enzyme downstream of Ngly1, nothing should have happened. This was truly a case of serendipity."
Although the double knockout mice survived, they shared several defects that are similar to the symptoms observed in people with NGLY1-deficiency. As these mice aged, they developed characteristics such as bent spines, trembling, limb-clasping and shaking, and by 45 weeks, the survival rate was reduced to 60%. These mice could therefore be useful model mice for developing treatments for the human genetic disorder.
Another factor affecting survival and symptoms turned out the be the genetic background of the mice, that is, the genotypes of all genes related to Ngly1 and Engase, which likely affect how they function. When mice were crossed with an outbred strain, the single Ngly1 knockout proved less lethal, and the double knockout proved to be even more helpful, with mice only showing hind-limb clasping after 30 weeks.
These findings show that the biological processes involved are quite complicated. Despite this however, it is clear that preventing ENGase from acting can alleviate symptoms of Ngly1 deficiency in mice. Figuring out which aspects of the genetic background help reduce symptoms is perhaps a long-term goal.
"For now, the next step," says the lead author, "will be to isolate an in vivo inhibitor for ENGase and determine whether it can improve the symptoms related to NGLY1-deficiency. As we do not know much about the pathophysiology of the disorder, this might help us find potential targets for therapy, but also might lead to a better understanding of other diseases. Such chains of unexpected results are the beauty of basic science!"
http://www.riken.jp/en/pr/press/2017/20170422_1/
http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006696
A mouse model for a devastating genetic deficiency
- 1,796 views
- Added
Edited
Latest News
How protein synthesis in de…
By newseditor
Posted 22 Apr
Atlas of mRNA variants in d…
By newseditor
Posted 22 Apr
Mapping microbiome in metas…
By newseditor
Posted 22 Apr
Full-length mRNA packaged i…
By newseditor
Posted 22 Apr
Glucose-sensing mechanism t…
By newseditor
Posted 21 Apr
Other Top Stories
Immunotherapy against clotting factor to protect neuroinflammation…
Read more
How gene activity shapes immunity across species
Read more
Glutamine metabolism affects T cell signaling and function
Read more
Nature of immune cells in the human brain disclosed
Read more
Immune cells could hold key to therapies for spinal cord injuries
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Neuronal activity rapidly r…
By newseditor
Posted 22 Apr
A perspective on muscle phe…
By newseditor
Posted 22 Apr
Foxp1 suppresses cortical a…
By newseditor
Posted 22 Apr
Single-cell long-read seque…
By newseditor
Posted 22 Apr
Unlocking potential: the ro…
By newseditor
Posted 22 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar